Subscribe

Study Summaries

NRG-GY023: Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.

ARIEL 4

PALETTE STUDY - Pazopanib for sarcoma

Fulvestrant + Abemaciclib

The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors

CHIPOR Trial: Secondary Debulking and HIPEC in Platinum Sensitive Recurrence

HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer

PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (Overall Survival)

Olaparib combined with bevacizumab provided a OS benefit for HRD-positive ovarian cancer patients.

Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer

Adjuvant Pembrolizumab did not improve DFS in high-risk endometrial cancer population

Korean HIPEC trial - IDS patients only 2023

HIPEC combined with ICS significantly improved PFS and OS in advanced-stage ovarian cancer patients, without increasing the rate of severe postoperative complications. A notable reduction in peritoneal recurrence may contribute to the OS improvement.

Korean HIPEC trial

The addition of HIPEC after interval cytoreductive surgery following neoadjuvant chemotherapy provided significant improvements in PFS and OS.

Interlace Trial

Induction chemotherapy followed by chemoradiotherapy significantly improves both progression-free survival and overall survival in patients with locally advanced cervical cancer compared to chemoradiotherapy alone.